If I were running Merck I would review ASCO updates to see if there are other complementary immune therapies for Keytruda Then make an offer for IMM before approval looks imminent
It won’t get a lot cheaper
- Forums
- ASX - By Stock
- Merck conundrum
IMM
immutep limited
Add to My Watchlist
0.00%
!
24.5¢

If I were running Merck I would review ASCO updates to see if...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
24.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $368.7M |
Open | High | Low | Value | Volume |
25.0¢ | 25.3¢ | 24.5¢ | $245.6K | 993.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
9 | 17029 | 24.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
25.0¢ | 649537 | 13 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
9 | 17029 | 0.245 |
21 | 309712 | 0.240 |
12 | 439022 | 0.235 |
16 | 354427 | 0.230 |
12 | 411466 | 0.225 |
Price($) | Vol. | No. |
---|---|---|
0.250 | 645381 | 11 |
0.255 | 332279 | 12 |
0.260 | 757509 | 10 |
0.265 | 112843 | 4 |
0.270 | 41600 | 3 |
Last trade - 11.10am 17/06/2025 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
RC1
REDCASTLE RESOURCES LIMITED
Ronald Miller, Non-Executive Director
Ronald Miller
Non-Executive Director
SPONSORED BY The Market Online